	[	Date of Visit:				
Dr.	5	Subject ID:	5.5			
		Follow	Up	Visits		
	Da	ate of Visit:				
U Week 4	UWeek 8	U Week 12		Veek 24	UWeek 36	□ Week 48
	U Week 60	□ Week 72	[	🗆 Week 84	U Week 96	
□ Adverse Events						
🗆 Concomitant Me	dications			•	•• • • •	ion was added to those activities visits. Now a third party will be
Validated Investi	gator's Assessme	ent (vIGA)			•	y was intentionally skipped.
🗆 Eczema Area Sev	verity Index (EASI	)				
□ Tanner Staging (i	if applicable-Only	7 Week 24, 48, a	nd 7	2) 🗆 N/A		
TB Risk Assessme	ent Form/ TB tes	t (Only on Week	( 48)	C N/A		
🗆 Chest X-ray (Onl	y on Week 48-if	applicable per T	B Ris	k Assessme	nt Form) 🛛 N/A	
Vital Signs						
Physical Exam (E)	xcept week 8) 🛛	N/A				
🗆 12 Lead ECG (On	ly on Week 48) 🗆	I N/A				
□ Urinalysis						
□ Urine pregnancy test (if applicable) □ N/A						
Blood Draw						
PK Samples (If ap	oplicable) 🛛 N/A					

 $\hfill\square$  Dosing Diary and Compliance Review

Dispense Study Drug

□ Dispense Home Urine Pregnancy Tests (if applicable) □ N/A

ClinCard

□ Scheduling

□ Requisition

Pages 1 of 6 v. 01.9.2022

SC:	Date:	

	э.		
	Date of Visit:		
Dr.	Subject ID:		
duarca Evanta			$\frown$
dverse Events			The "N/A" (not
Where there any change	es to the patient's medical sta	itus? 🗆 Yes 🗆 No	applicable) option was
If yes, was adverse ever	its chart updated? 🛛 Yes	🗆 No 🗆 N/A 🚺	added to those activities which don't apply in all
Concomitant Medications			situations.
			2 Cuidanas en obtaining
Where there any change	es to the patient's medication	s? 🗆 Yes 🗆 No < 2	Guidance on obtaining vital signs was added to
If yes, was con meds cha	art updated? 🗆 Yes 🗆 No	o □ N/A 2	aid the coordinator.
		2	3
alidated global Assessment	(VIGA)		Modelling the format of the time of vital
Was the assessment do	ne? (separate form): 🛛 Yes	□No	assessment ensures
czema Area and Sensitivity	Index (EASI)		consistency of data.
Was the assessment do	ne? (separate form): □Yes	□No	
anner Staging (Weeks 24, 4	8, and 72 Only)		
Was the assessment do	ne? (separate form): □Yes [		
B Risk Assessment Form (Or	nly on Week 48)		
Was the Risk Assessmer	it Form completed? (separate	form):  Yes  No N/	
hest X-ray (only if applicable p	er TB Risk Assessment Form)		
Completed: Date/Time:		□ N/A	
/ital Signs	2		
Obtain prior to blood collecti			
ime of Vitals assessment (24	:00):3		
lood Pressure: /	mmHg		
	mining		$\frown$

	Where was blood press	ure taken (specify side and location of body):
Pulse:	beats/min	
Respira	atory Rate:	breaths/min
Tempe	rature: DF	□C
. [	Method of temperature	e collection: 🗆 tympanic 💷 other:2
-Ensure	e subject is wearing light	weight clothing and no shoes 2
Weight	t: 🗆 lb	□kg
Height	: □in	□cm
Pages 2	2 of 6 v. 01.9.2022	SC:Date:

		Date of Visit:	
Dr.		Subject ID:	
Date:/	/	Physical Exam (Except Week 8) Time:	No changes were made to this pag
Body System		Result	Abnormality
General Appearance	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Head, Neck, Ears, Nose, Throat, Eyes	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Dermatologic	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Cardiovascular	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Respiratory	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Abdomen	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Neurological	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Musculoskeletal	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
Extremities	Normal Not Done significant	<ul> <li>Abnormal, clinically significant</li> <li>Abnormal, not clinically</li> </ul>	
	Normal	Abnormal, clinically significant	

Lymph Nodes	Not Done significant	Abnormal, not clinically	
Other (specify):	Normal	Abnormal, clinically significant Abnormal, not clinically	
	significant		

PI Signature:	Date:	
---------------	-------	--

# Pages 3 of 6 v. 01.9.2022

SC:\_\_\_\_\_Date: \_\_\_\_\_

	Date of Visit:
Dr.	Subject ID:

### 12-Lead ECG (Only on Week 48) N/A

-Obtain prior to blood collection	(1)
-Ensure subject has been in the supine position for 5 minutes befo	ore recording
Date of ECG:// Time of ECG:	_:
dd mmm yyyy hl	h mm
Investigator's Interpretation:	Guidance added to aid the coordinator.
Normal	
Abnormal, clinically significant	
Abnormal, not clinically significant	
Not evaluable	
Abnormal Findings:	
<ul> <li>Abnormal rhythm</li> <li>Abnormal conduction</li> <li>Axis QRS &gt;+120</li> <li>Axis QRS &lt; -30</li> <li>Axis indeterminate</li> <li>Left Ventricular hypertrophy</li> <li>Right Ventricular hypertrophy</li> <li>Q wave abnormality</li> <li>ST segment depressed &gt; +1mm</li> <li>segment elevated&gt; =1mm</li> </ul>	<ul> <li>T wave abnormality</li> <li>U wave abnormality</li> <li>QTcF prolongation</li> <li>ST</li> <li>Other abnormality, specify:</li> </ul>
If QTcF prolongation, QTCF =msec (M: >430MSE	C; F: >450MSEC)
If QTCF prolongation, baseline =msec (prior to drug	exposure)
	ite:2
Urinalysis	
Was the urinalysis performed?   Yes  No  N/A	2 PI signature and date
Time performed::	added as not present in past version.
PREGNANCY TEST - IF APPLICABLE	



	Date of Visit:	
Dr.	Subject ID:	

#### **PK Sampling**

(If dose is modified based on analysis of data from Part 2, sample will be collected prior to dosing on visit day and at subsequent visit.)

1

"NA" added.

5

parent/guardians.

1

(Sample will not be collected when dose is changed due to change in subject's weight.)

Was the blood draw performed? 
\_Yes 
\_No 
N/A: Dose not changed since last visit

Time performed: \_\_\_\_\_:\_\_\_\_\_

#### **Drug Return**

Were kits from prior visit returned? 
visit Yes 
No

If yes, what kits were returned? (please specify if kits were empty when returned)

If no, was patient/guardian reminded to bring kits at next visit?  Yes  No  N/A 2	A new question to
Dosing Diary and Compliance Review	remind staff to remind participants
Formulation:  a tablet (QD) a Solution (BID) 3 Date & Time of second to last dose:	was added.
	Specific questions to record dosing added.
Was Dosing Diary reviewed and signed by coordinator? □ Yes □ No Was new Dosing diary dispensed? □ Yes □ No	
Compliance	4
<ul> <li>(240 mg X # of bottles dispensed) =total weight of all drug beginning</li> <li>240 mg X =</li> <li>Unit variance of 1<sup>st</sup> bottle + unit variance of 2<sup>nd</sup> bottle+ etc. (for totally # of bottles) Unit variance (drug used): weight of bottle at beginning-weight of bottle after return</li> <li>++ = (total unit variance)</li> <li>Total unit variance / # of days between visit= average dose given per day</li> </ul>	An entire section on dosage compliance added, with significant detail regarding amount per bottle and daily dosage.
<ul> <li>Average dose given per day / prescribed daily dose = % compliance</li> <li>/ = %</li> </ul>	

Was drug compliance reviewed with patient/guardian of patient?

Was patient between 80% and 120% compliant? 

Yes No

If no, was patient re-educated on drug compliance? 

Yes 
No

## Dispense Drug 5

1	Was study drug dispensed and dosing instructions reviewed?  Ves  No	Guidance added
	-See dispensation confirmation and copy of dispensed kits for verification	here regarding
	Was there a change is patient dosing?  _Yes  _No	dosage dispensation and
ſ	Was patient/guardian instructed to return all drug in possession at next visit?   Yes  No	to account for
I	Did patient/guardian verbalize understanding on compliance and dosing instructions? $\Box$ Yes	nd dosing instructions?   Yes minors with

Pages 5 of 6 v. 01.9.2022

	Date of Visit:	
Dr.	Subject ID:	

#### **Dispense Home Urine Pregnancy Tests**

(females of childbearing potential only)



## Pages 6 of 6 v. 01.9.2022

SC:\_\_\_\_\_Date: \_\_\_\_\_